CPI CPI Adverse Event Management & Reporting 1 — Questions and Answers
Question 1: Which of the following meets the FDA definition of a Serious Adverse Event (SAE) in a clinical trial?
- Mild nausea lasting less than 24 hours
- Hospitalization required due to a study-related complication (Correct answer)
- A temporary decrease in blood pressure without clinical significance
- A minor rash resolving with topical treatment
Correct answer: Hospitalization required due to a study-related complication
An SAE is any adverse event that results in death, life-threatening risk, hospitalization, disability, congenital anomaly, or requires medical intervention to prevent serious outcomes.
Question 2: Within what timeframe must an investigator report a fatal or life-threatening unexpected SAE to the FDA under 21 CFR 312.32?
- Within 7 calendar days (Correct answer)
- Within 15 calendar days
- Within 30 calendar days
- Within 48 hours
Correct answer: Within 7 calendar days
Fatal or life-threatening unexpected serious adverse drug reactions must be reported to the FDA as an IND safety report within 7 calendar days of the investigator becoming aware.
Question 3: What does it mean for an adverse drug reaction to be 'unexpected' in a clinical trial context?
- The event occurred at a higher frequency than anticipated
- The nature, severity, or specificity is not consistent with what is described in the Investigator's Brochure (Correct answer)
- The event has never been reported in the medical literature
- The investigator did not anticipate it based on the subject's medical history
Correct answer: The nature, severity, or specificity is not consistent with what is described in the Investigator's Brochure
An unexpected adverse reaction is one whose nature, severity, or specificity is not consistent with the current Investigator's Brochure or product labeling.
Question 4: Which form is used to report post-market safety problems with FDA-regulated products to the FDA?
- FDA Form 1572
- FDA MedWatch Form 3500 (Correct answer)
- FDA Form 483
- IND Annual Report Form
Correct answer: FDA MedWatch Form 3500
MedWatch Form 3500 (voluntary) or 3500A (mandatory for industry) is the FDA's safety reporting form for adverse events with regulated products.
Question 5: What is the key distinction between an 'adverse event' (AE) and an 'adverse drug reaction' (ADR)?
- An AE occurs only in the treatment group; an ADR can occur in placebo groups
- An AE is any untoward occurrence regardless of causality; an ADR implies a causal relationship to the study drug (Correct answer)
- An ADR must be serious; an AE can be of any severity
- An AE requires FDA reporting; an ADR is reported only to the sponsor
Correct answer: An AE is any untoward occurrence regardless of causality; an ADR implies a causal relationship to the study drug
An adverse event is any unfavorable occurrence during a study regardless of drug relationship, while an adverse drug reaction implies a reasonable causal relationship to the investigational product.
Question 6: Who is primarily responsible for reporting SAEs to the clinical trial sponsor?
- The IRB chairperson
- The principal investigator or sub-investigator at the site (Correct answer)
- The FDA district office
- The Data Safety Monitoring Board
Correct answer: The principal investigator or sub-investigator at the site
The principal investigator is responsible for promptly reporting all SAEs to the sponsor, who then evaluates and submits required safety reports to the FDA.
CPI CPI Adverse Event Management & Reporting 1
Which of the following meets the FDA definition of a Serious Adverse Event (SAE) in a clinical trial?